8/1011 sources · 4 publishersUpdated Nov 2, 18:26 UTC
Axsome reports strong Q3 growth as AUVELITY sales accelerate
+1 new source since this summary was written
On November 2, Axsome reported Q3 2026 revenue of $259.7 million, up 51.9% year over year, and a GAAP loss of $0.25 per share. AUVELITY generated $207.6 million, while SUNOSI contributed $48.2 million. Axsome also began the Phase 3 SUMMIT study of AXS-05 in smoking cessation.
Why it matters
The results provide updated evidence of commercial growth across Axsome’s approved products, led by AUVELITY. The company said its current cash balance should support operations until cash flow turns positive, which could limit near-term financing needs if that expectation holds.
Key facts
- 1Axsome recorded a quarterly net loss of $12.9 million, compared with $47.2 million in Q3 2025. rttnews.com
- 2AUVELITY prescriptions totaled approximately 302,000 in the quarter, increasing 40% year over year and 14% sequentially. rttnews.com
- 3Research and development expense reached $50.6 million, while selling, general and administrative expense rose to $203.1 million. rttnews.com
- 4Cash and cash equivalents stood at $313.9 million on September 30, 2026. rttnews.com
- 5Axsome expects topline results from the Phase 3 SUMMIT trial of AXS-05 in the second half of 2027. rttnews.com
Open questions
- Pre-release materials did not agree on the consensus revenue or EPS estimates used to measure the earnings beat.
- One recap identifies the quarter as Q3 2025, while the other earnings materials identify it as Q3 2026.
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.